How Has The Myasthenia Gravis Treatment Market Size Evolved In Recent Years?
The myasthenia gravis treatment market has seen considerable growth due to a variety of factors.
•In recent times, the market size for the treatment of myasthenia gravis has seen a significant surge. It is predicted to increase from $1.55 billion in 2024 to $1.66 billion in 2025, representing a compound annual growth rate (CAGR) of 7.3%.
This growth during the historic period can be traced back to factors such as the inception of cholinesterase inhibitors, the advent of thymectomy procedures, the introduction of immunosuppressive therapies, the emergence of plasma exchange, and improved patient advocacy.
What Are The Estimated Market Size And Expected Annual Growth Rates For Global Myasthenia Gravis Treatment Market?
The myasthenia gravis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for myasthenia gravis treatment is set to witness substantial expansion in the forthcoming years, ballooning to $2.26 billion by 2029 with an 8.0% compound annual growth rate (CAGR).
This growth over the projection period is influenced by factors such as biologics and monoclonal antibodies, genomic and precision medication, upcoming immune modulators, neuroprotective approaches and biosimilar drugs. Key trends speculated to drive the market during the forecast timeline include digital therapy methods, joint research initiatives, patient-oriented strategies, application of real-world evidence, and ongoing safety monitoring.
Which Key Drivers Are Propelling The Myasthenia Gravis Treatment Market's Growth?
The increase in myasthenia gravis cases is anticipated to fuel the expansion of the market for its treatment. Characterized as an autoimmune neuromuscular disease where the afflicted patients suffer from fatigue and weakness in skeletal muscles, myasthenia gravis treatment involves comprehensive health care services and patient care to counteract the ailment. Hence, the rise in the incidence of this condition is enhancing the sales in the market treating it. Notable data was revealed in January 2022 by the National Organization for Rare Disorders, a US non-profit supporting individuals with rare diseases, stating that autoimmune myasthenia gravis had an estimated rate of 14–40 per 100,000 individuals in the US alone. Another report published by the American Journal of Managed Care, a US-based peer-reviewed journal, in April 2024, estimated an average of 1,800 diagnoses of myasthenia gravis (MG) each year, which calculated an annual incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Consequently, the increased incidence of myasthenia gravis is contributing positively to the growth of its treatment market.
What Are The Key Segments Within The Global Myasthenia Gravis Treatment Market?
The myasthenia gravis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses
Subsegments:
1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies
Pre-Book The Myasthenia Gravis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Myasthenia Gravis Treatment Market?
The advancement of novel treatments is an increasing trend in the sector of myasthenia gravis treatment. Several leading corporations in this market are concentrating their efforts on the creation of innovative solutions in order to retain their market presence. For example, in October 2023, UCB Pharma, a pharmaceutical entity from Belgium, received approval from the US Food and Drug Administration (FDA) for Zilucoplan. This medication is utilized to treat adult patients with generalized myasthenia gravis (gMG) who are found to have anti-acetylcholine receptor (AChR) antibodies. This authorization brings forth a fresh approach towards managing gMG, typically identified by muscular weakness caused by an autoimmune reaction. ZILBRYSQ is especially significant as it is a self-injected, daily-use subcutaneous complement C5 inhibitor. This results in a more accessible alternative to the customary intravenous therapies, which have been the norm for managing gMG.
Who Are the Key Players in the Myasthenia Gravis Treatment Market?
Major companies operating in the myasthenia gravis treatment market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Novartis AG
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• Biogen Idec
• Astellas Pharma Inc.
• CSL Limited
• Chugai Pharmaceutical Co. Ltd.
• Grifols S.A
• UCB Inc.
• Mitsubishi Tanabe Pharma Corp.
• Genentech Inc.
• Horizon Therapeutics plc
• Amneal Pharmaceuticals Inc.
• Kedrion SpA
• CuraVac Inc.
• AryoGen Pharmed
• RemeGen Co. Ltd.
• Kashiv BioSciences LLC
• Immunovant Inc.
• Cabaletta Bio Inc.
• Argenx SE
• NMD Pharma A/S
• Cartesian Therapeutics Inc.
• DAS Therapeutics Inc.
• Harbour BioMed Holdings Ltd.
• AnTolRx Inc.
• CytoDyn Inc.
• Ahead Therapeutics
What are the Regional Insights into the Myasthenia Gravis Treatment Market?
North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
